RxDoctor Payments Data

Forster Ruhl, MD

Family Medicine · Senatobia, MSNPI 1972606358

Payments from drug & device makers

$369in general payments, 2019–2025

Across 21 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$86
  • Merck$44
  • Lilly USA, LLC$34
  • Kowa Pharmaceuticals America, Inc.$31
  • GSK$30
  • Sunovion Pharmaceuticals Inc.$28
  • plus $115 from 7 others

What the payments were for

  • Food & beverage$33992%
  • Education$308%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$369 in reported general payments places this provider in the 40th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$127,338
Medicare patients
363
Services billed
2,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$35,745
JardianceEmpagliflozin31$32,075
OzempicSemaglutide35$31,491
EliquisApixaban43$27,260
TrulicityDulaglutide20$18,433
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,304
LinzessLinaclotide27$13,848
VascepaIcosapent Ethyl18$13,021
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$11,871
FarxigaDapagliflozin Propanediol14$10,929
Tresiba Flextouch U-100Insulin Degludec17$7,991
JanumetSitagliptin Phos/Metformin Hcl13$6,386
JanuviaSitagliptin Phosphate11$6,008
BelsomraSuvorexant12$4,993
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp16$4,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$34$54,17956 claims
Novo NordiskOzempic$14$31,49135 claims
PfizerEliquis$13$27,26043 claims
GSKTrelegy Ellipta$30$18,30429 claims
MerckJanumet, Januvia, Belsomra$44$17,38736 claims
AbbVieLinzess, Synthroid$86$15,72356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Senatobia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →